ME Stock Overview
Operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
23andMe Holding Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.91 |
| 52 Week High | US$20.40 |
| 52 Week Low | US$4.80 |
| Beta | 1.21 |
| 11 Month Change | -26.80% |
| 3 Month Change | -44.46% |
| 1 Year Change | -69.99% |
| 33 Year Change | -97.74% |
| 5 Year Change | n/a |
| Change since IPO | -97.49% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation
Apr 16
Risks Still Elevated At These Prices As 23andMe Holding Co. (NASDAQ:ME) Shares Dive 26%
Mar 02We're Keeping An Eye On 23andMe Holding's (NASDAQ:ME) Cash Burn Rate
Jul 1323andMe Holding Co. (NASDAQ:ME) Investors Are Less Pessimistic Than Expected
Jun 1523andMe: Disappointing Results Could Mean Potential Acquisition Target
Sep 2723andMe: Treacherous Path To Profitability
Aug 2623andMe drops 8% as CFO resigns
Aug 1923andMe Holding Co. (NASDAQ:ME) Just Reported, And Analysts Assigned A US$5.00 Price Target
Aug 1123andMe Q1 2023 Earnings Preview
Aug 0723andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
Jun 1523andMe: A Genetics Innovator Positioned For Growth
Feb 19Need To Know: Analysts Are Much More Bullish On 23andMe Holding Co. (NASDAQ:ME) Revenues
Feb 1823andMe: No Surprises With Recent Earnings, But Long-Term Story Remains Positive
Nov 2123andMe Stock: Continued Drug-Development Progress Can Deliver Long-Term Gains
Oct 03Companies Like 23andMe Holding (NASDAQ:ME) Are In A Position To Invest In Growth
Sep 1723andMe: New Therapeutic Pipeline And PGS Product Growth Catalyzed By +$696M In SPAC Funding
Jul 19Shareholder Returns
| ME | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -15.9% | -4.4% | 0.8% |
| 1Y | -70.0% | 4.0% | 38.3% |
Return vs Industry: ME underperformed the US Healthcare industry which returned 4% over the past year.
Return vs Market: ME underperformed the US Market which returned 36% over the past year.
Price Volatility
| ME volatility | |
|---|---|
| ME Average Weekly Movement | 11.8% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ME's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ME's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 571 | Anne Wojcicki | www.23andme.com |
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
23andMe Holding Co. Fundamentals Summary
| ME fundamental statistics | |
|---|---|
| Market cap | US$126.86m |
| Earnings (TTM) | -US$631.48m |
| Revenue (TTM) | US$199.19m |
0.6x
P/S Ratio-0.2x
P/E RatioIs ME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ME income statement (TTM) | |
|---|---|
| Revenue | US$199.19m |
| Cost of Revenue | US$109.98m |
| Gross Profit | US$89.21m |
| Other Expenses | US$720.69m |
| Earnings | -US$631.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.44 |
| Gross Margin | 44.79% |
| Net Profit Margin | -317.03% |
| Debt/Equity Ratio | 0% |
How did ME perform over the long term?
See historical performance and comparison